We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

BioVendor Group

BioVendor Group is an international group of biotechnology companies (BioVendor LM, BioVendor R&D, TestLine, ViennaLa... read more Featured Products: More products

Download Mobile App




Urine Neutrophil Gelatinase-Associated Lipocalin Predicts Acute Kidney Injury

By LabMedica International staff writers
Posted on 15 Nov 2022

Despite the increasing heterogeneity of etiology, making a definitive and timely diagnosis of acute kidney injury (AKI) remains challenging. More...

Currently, the diagnosis of AKI is still based on elevated serum creatinine concentration or decreased urinary excretion. However, increased serum creatinine and decreased urine volume usually occur 48 hours after renal injury.

Contrast-associated acute kidney injury (CA-AKI) is an early complication after percutaneous coronary intervention (PCI). Depending on the study subjects, the rate of acute kidney injury can occur from 4.2% to 50%. CA-AKI after PCI is often associated with contrast drugs, hemodynamic instability, old age, pre-existing chronic kidney disease, or a combination of diabetes and hypertension.

Medical Scientists at the Vietnam Military Medical University (Hanoi, Vietnam) included in a study 509 patients with chronic coronary artery disease, indicated for planned percutaneous coronary intervention at two centers. The patients were divided into two groups: group 1, 153 elderly patients ≥70 years old and group 2, 356 patients <70 years old. The team collected fasting morning venous blood plasma to determine concentrations of hs-CRP, hs-TnT, ALT, AST, cholesterol, triglyceride, HDL-C, LDL-C, electrolyte, glucose, urea, and creatinine.

The patient's 24 hour-urine sample was collected on the day before the procedure. After 24 hours, the team measures the urine volume, took 5 mL of urine to determine the neutrophil gelatinase-associated lipocalin (NGAL) level, and then calculated the 24-h urine NGAL concentration. Urine NGAL was measured by the Human Lipocalin-2/NGAL ELISA kit (BioVendor, Brno, Czech Republic) based on the sandwich enzyme immunoassay method. All patients had their glomerular filtration rate (eGFR) calculated based on the MDRD formula.

The investigators reported that the ratio of CA-AKI in group 1 was 23.5% which was higher than that of group 2 (8.7%). Urine NGAL level in group 1 was significantly higher than that of group 2 (31.3 (19.16–55.13) ng/mL versus 19.86 (13.21–29.04) ng/mL. At a cut-off value of 44.43 ng/ml, urinary NGAL had a predictive value for CA-AKI in all patients (AUC = 0.977). Especially at a cut-off value of 44.14 ng/mL, urinary NGAL had a predictive value for CA-AKI in elderly patients (AUC = 0.979).

The authors concluded that the rate of CA-AKI after PCI in elderly patients was 23.5%. Urine NGAL before PCI has a good predictive value for CA-AKI in elderly patients who received planned percutaneous coronary intervention. The study was published on November 10, 2022 in the Journal of Clinical Laboratory Analysis.

Related Links:
Vietnam Military Medical University
BioVendor


Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
Respiratory Syncytial Virus Test
OSOM® RSV Test
New
Urine Drug Test
Instant-view® Phencyclidine Urine Drug Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Switching to an experimental drug after liquid biopsy detection of breast cancer recurrence can improve outcomes (Photo courtesy of Shutterstock)

Treatment Switching Guided by Liquid Biopsy Blood Tests Improves Outcomes for Breast Cancer Patients

Standard treatment for patients with advanced estrogen receptor (ER)-positive, HER2-negative breast cancer, a subtype driven by estrogen receptors that fuel tumor growth, often involves aromatase inhibitors,... Read more

Pathology

view channel
Image: Microscopy image of invasive breast cancer cells degrading their underlying extracellular matrix (Photo courtesy of University of Turku)

Visualization Tool Illuminates Breast Cancer Cell Migration to Suggest New Treatment Avenues

Patients with breast cancer who progress from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) face a significantly worse prognosis, as metastatic disease remains incurable.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.